Compared with sulfonylureas, GLP-1R agonists were reported to be associated with a 30% lower risk of severe AECOPD (3.5 vs. 5.0 events per 100 person-years; HR 0.70; 95% CI: 0.49–0.99) and moderate AECOPD (HR 0.63; 95% CI: 0.43–0.94) in patients with T2DM and COPD [92]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.